Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025
Verona Pharma (NASDAQ:VRNA) announced the presentation of two posters featuring additional analyses from its Phase 3 ENHANCE studies of Ohtuvayre® (ensifentrine) for COPD treatment at the upcoming ERS International Congress 2025.
Ohtuvayre, representing the first novel inhaled COPD maintenance treatment mechanism in over 20 years, is a first-in-class dual inhibitor of PDE3 and PDE4 enzymes that uniquely combines bronchodilator and anti-inflammatory effects. The posters will analyze the drug's impact on lung function, exacerbation rates, COPD symptoms, and quality of life based on baseline dyspnea levels.
Verona Pharma (NASDAQ:VRNA) ha annunciato la presentazione di due poster con analisi aggiuntive dai suoi studi di fase III ENHANCE su Ohtuvayre® (ensifentrina) per il trattamento della BPCO all imminente Congresso Internazionale ERS 2025.
Ohtuvayre, che rappresenta il primo meccanismo di mantenimento inalato per BPCO introdotto in oltre 20 anni, è una terza classe di inibitori duali delle enzimi PDE3 e PDE4 che combina in modo unico effetti broncodilatatori e antinfiammatori. I poster analizzeranno l impatto del farmaco sulla funzione polmonare, tassi di esacerbazione, sintomi della BPCO e qualità di vita in base ai livelli di dispnea basali.
Verona Pharma (NASDAQ:VRNA) anunció la presentación de dos pósteres con análisis adicionales de sus ensayos de fase 3 ENHANCE de Ohtuvayre® (ensifentrina) para el tratamiento de la EPOC en el próximo Congreso Internacional ERS 2025.
Ohtuvayre, que representa el primer mecanismo de mantenimiento inhalado para EPOC en más de 20 años, es un inhibidor dual de PDE3 y PDE4 de clase pionera que combina de manera única efectos broncodilatadores y antiinflamatorios. Los pósteres analizarán el impacto del fármaco en la función pulmonar, tasas de exacerbaciones, síntomas de EPOC y calidad de vida según los niveles de disnea basales.
Verona Pharma (NASDAQ:VRNA)는 Ohtuvayre® (ensifentrine)의 3상 ENHANCE 연구에서의 추가 분석을 담은 두 편의 포스터를 다가오는 ERS 국제 학술대회 2025에서 발표한다고 밝혔습니다.
Ohtuvayre는 20년 만에 처음으로 새롭게 도입된 흡입형 BPCO 유지 치료 메커니즘를 대표하며, PDE3 및 PDE4 효소를 이중으로 억제하는 1급(in-class) 약제로서 기관지확장제와 항염증 효과를 독특하게 결합합니다. 포스터들은 기저 호흡곤란 수준에 따른 폐 기능, 악화율, COPD 증상 및 삶의 질에 대한 약물의 영향을 분석할 것입니다.
Verona Pharma (NASDAQ:VRNA) a annoncé la présentation de deux posters comportant des analyses additionnelles issues de ses essais de phase 3 ENHANCE concernant Ohtuvayre® (ensifentrine) pour le traitement de la BPCO au prochain Congrès international ERS 2025.
Ohtuvayre, représentant le premier mécanisme de maintenance inhalé pour la BPCO en plus de 20 ans, est un inhibiteur dual de la PDE3 et PDE4 de première classe qui combine de façon unique des effets bronchodilatateurs et anti inflammatoires. Les posters analyseront l impact du médicament sur la fonction pulmonaire, les taux d exacerbation, les symptômes de la BPCO et la qualité de vie selon les niveaux de dyspnée basales.
Verona Pharma (NASDAQ:VRNA) hat die Vorstellung von zwei Postern angekündigt, die zusätzliche Analysen aus ihren Phase-3-ENHANCE-Studien von Ohtuvayre® (ensifentrine) für die Behandlung der COPD beim kommenden ERS International Congress 2025 enthalten.
Ohtuvayre, das den ersten neuen inhalativen Wartungsbehandlungsmechanismus für COPD seit über 20 Jahren repräsentiert, ist ein First-in-Class-Dualinhibitor der Enzyme PDE3 und PDE4, der Bronchodilatation und Antiinflammationswirkungen auf einzigartige Weise vereint. Die Poster werden die Auswirkungen des Medikaments auf die Lungenfunktion, Exazerbationsraten, COPD-Symptome und Lebensqualität basierend auf dem Ausgangsniveau der Dyspnoe analysieren.
Verona Pharma (NASDAQ:VRNA) أعلنت عن عرض لافتتين يتضمنان تحليلات إضافية من دراسات المرحلة الثالثة ENHANCE لدوائها Ohtuvayre® (ensifentrine) لعلاج مرض الانسداد الرئوي المزمن في المؤتمر الدولي ERS 2025 القادم.
يمثل Ohtuvayre أول آلية صيانة استنشاقية جديدة لمرض الانسداد الرئوي المزمن خلال أكثر من 20 عامًا، وهو مثبط ثنائي من فئة PDE3 وPDE4 يجمع بطريقة فريدة بين تأثيرات موسع الشعب الهوائية ومضاد للالتهابات. ستحلل الملصقات تأثير الدواء على وظائف الرئة ومعدلات تفاقم المرض وأعراض COPD ونوعية الحياة وفقًا لمستويات ضيق النفس الأساسية.
Verona Pharma (NASDAQ:VRNA)宣布将在即将举行的ERS国际大会2025上发布两份海报，包含其Phase 3 ENHANCE研究中关于
Ohtuvayre，代表着二十多年里首个新的吸入性COPD维持治疗机制，是一种第一类双重PDE3和PDE4抑制剂，独特地结合了支气管扩张和抗炎作用。海报将基于基线呼吸困难水平，分析该药物对肺功能、疾病恶化率、COPD症状和生活质量的影响。
- None.
- None.
Posters support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population
LONDON and RALEIGH, N.C., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces two posters on additional analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (“COPD”), will be presented at the European Respiratory Society (“ERS”) International Congress 2025. The abstracts are available to conference participants on the ERS website and will be published in an upcoming issue of the peer reviewed publication, European Respiratory Journal.
Ohtuvayre (ensifentrine) is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase 3 and 4 (“PDE3 and PDE4”) that combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule. Ohtuvayre is the first novel inhaled mechanism for the maintenance treatment of COPD in more than 20 years.
The posters highlight subgroup analyses of the benefits of ensifentrine on lung function, rate and risk of exacerbations, and COPD symptoms, including dyspnea, and quality of life according to baseline dyspnea level.
Details of Verona’s posters are listed below and linked to the ERS website:
Poster 3613: The effect of ensifentrine on COPD symptoms and quality of life according to baseline dyspnea level
Presenter: Jadwiga A. Wedzicha, MD, Professor of Respiratory Medicine at the National Heart and Lung Institute, Imperial College London, UK
Session 306: Unblocking the airways: innovations in mucus-targeted therapy and novel data on phosphodiesterase inhibitors
Poster 3614: The effect of ensifentrine on lung function and exacerbations in patients with COPD according to baseline dyspnea
Presenter: Frits M.E. Franssen, MD, Head of the Department of Respiratory Medicine, Maastricht University Medical Center, The Netherlands
Session 306: Unblocking the airways: innovations in mucus-targeted therapy and novel data on phosphodiesterase inhibitors
For further information please contact:
| Verona Pharma plc | Tel: +1-844-341-9901 |
| Victoria Stewart, Senior Director of Investor Relations and Communications | IR@veronapharma.com |
| Argot Partners US Investor Enquiries | Tel: +1-212-600-1902 verona@argotpartners.com |
| Ten Bridge Communications International / US Media Enquiries | Tel: +1-781-316-4424 tbcverona@tenbridgecommunications.com |
| Wendy Ryan | |
About Ohtuvayre (ensifentrine)
Ohtuvayre is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Verona has evaluated nebulized Ohtuvayre in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Ohtuvayre met the primary endpoint in both ENHANCE-1 and ENHANCE-2, demonstrating statistically significant and clinically meaningful improvements in lung function. A fixed-dose combination of ensifentrine and glycopyrrolate, a LAMA, is currently under development for the maintenance treatment of COPD.
About Verona Pharma
Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre™ (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in other respiratory diseases such as non-cystic fibrosis bronchiectasis. For more information, please visit www.veronapharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements. Words such as “anticipate,” “believe,” “plan,” “expect,” “intend,” “may,” “potential,” “prepare,” “possible” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the potential benefits and efficacy of our drug Ohtuvayre and future poster presentations and academic publications pertaining to Ohtuvayre.
These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to the efficacy of Ohtuvayre compared to competing drugs; and the other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended June 30, 2025 filed with the Securities and Exchange Commission (“SEC”) on August 6, 2025, as such factors may be updated from time to time in our other filings with the SEC. We disclaim any obligation to update or revise any forward-looking statement contained in this press release, even if subsequent events cause our views to change, except as required under applicable law.
FAQ
What will Verona Pharma (VRNA) present at the ERS International Congress 2025?
What makes Ohtuvayre unique in COPD treatment?
Who will present the VRNA posters at ERS Congress 2025?
When will the VRNA Phase 3 ENHANCE study analyses be published?
